Upstream Bio, Inc. 8K

Upstream Bio, Inc. announced second quarter 2026 financial results and clinical development milestones for verekitug, including completed Phase 2 COPD trial enrollment and plans to start Phase 3 trials in severe asthma and CRSwNP in Q1 2027, with cash runway expected through 2027.

On August 11, 2026, Upstream Bio, Inc. reported its financial results for the quarter ended June 30, 2026 and provided business updates, highlighting continued clinical progress with its lead TSLP-receptor antagonist verekitug across severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD), including remaining on track to initiate Phase 3 trials in severe asthma and CRSwNP in Q1 2027, completion of enrollment in the Phase 2 VENTURE COPD trial with data expected in the second half of 2027, strong retention in the VALOUR long-term extension study, and confirmation that its $261.3 million of cash, cash equivalents and short-term investments are expected to fund planned operations through 2027 despite a quarterly net loss of $39.7 million.

Filing Facts

CIK

2022626

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-343407

Alert Tier

6